Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial lutetium-177 dotatate for neuroendocrine tumor liver metastases
NL-OMON49314Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in apudoma (NET) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Tumor-to-non-tumor activity concentration ratio after first cycle. Started Aug 2018; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on NL-OMON49314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49314.